Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells by Boonsri, Boonyakorn et al.
Introduction
Cholangiocarcinoma (CCA) or bile duct cancer is a malig-
nant transformation of the epithelial cells lining the biliary 
tract. While in North America and Europe, it is relatively rare 
(2-4/100,000 deaths), but rapidly increasing in incidence [1], 
in Asia, it is a very significant problem. In Isan province in 
Thailand, a region of 26M people, it is one of the most com-
mon cancers (up to 112/100,000 people) where the primary 
risk factor for development of CCA is infection with the para-
sitic flatworm (Opisthorchis viverrini [OV]). CCA has a very 
poor prognosis worldwide, with a high mortality rate as 
a consequence of a lack of tools for early diagnosis, a poor 
understanding of the molecular biology of the cholangiocyte 
transformation, and a consequent lack of effective drug thera-
pies [2]. Tumor resection or, rarely, liver transplantation, are 
currently the only potentially curative treatment for CCA.
Gemcitabine and cisplatin combination have widely been 
used in advanced CCA and the combination is currently 
accepted as the standard treatment of care for first-line thera-
py in the United States and Europe. However, the outcome of 
using these drugs is still discouraging [3]. Recently, Hyung et 
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Purpose  The potential of members of the epidermal growth factor receptor (ErbB) family as drug targets in cholangiocarcinoma (CCA) 
has not been extensively addressed. Although phase III clinical trials showed no survival benefits of erlotinib in patients with advanced 
CCA, the outcome of the standard-of-care chemotherapy treatment for CCA, gemcitabine/cisplatin, is discouraging so we determined 
the effect of other ErbB receptor inhibitors alone or in conjunction with chemotherapy in CCA cells.
Materials and Methods  ErbB receptor expression was determined in CCA patient tissues by immunohistochemistry and digital-
droplet polymerase chain reaction, and in primary cells and cell lines by immunoblot. Effects on cell viability and cell cycle distribution 
of combination therapy using ErbB inhibitors with chemotherapeutic drugs was carried out in CCA cell lines. 3D culture of primary CCA 
cells was then adopted to evaluate the drug effect in a setting that more closely resembles in vivo cell environments. 
Results  CCA tumors showed higher expression of all ErbB receptors compared with resection margins. Primary and CCA cell lines 
had variable expression of erbB receptors. CCA cell lines showed decreased cell viability when treated with chemotherapeutic drugs 
(gemcitabine and 5-fluorouracil) but also with ErbB inhibitors, particularly afatinib, and with a combination. Sequential treatment of 
gemcitabine with afatinib was particularly effective. Co-culture of CCA primary cells with cancer-associated fibroblasts decreased 
sensitivity to chemotherapies, but sensitized to afatinib.  
Conclusion  Afatinib is a potential epidermal growth factor receptor targeted drug for CCA treatment and sequential treatment sched-
ule of gemcitabine and afatinib could be explored in CCA patients.    
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al. [4] showed maintenance of gemcitabine and cisplatin com-
bination is not associated with an improved survival outcome 
in advanced biliary tract cancer patients after progression.
Epidermal growth factor receptor (EGFR) or ErbB are 
effective therapeutic targets in many cancer types [5]. ErbB 
receptors and their downstream signaling pathways have 
been reported as key regulators of cancer cell proliferation, 
migration, metastasis, and angiogenesis and their high expre-
ssion correlates with a poor prognosis [6]. ErbB receptors 
belong to the membrane-anchored receptor tyrosine kinase 
ErbB/human epidermal growth factor receptor (HER) fam-
ily consisting of EGFR (HER1/ErbB1), HER2 (ErbB2), HER3 
(ErbB3), and HER4 (ErbB4) [7]. Ligand activation of EGFR 
results in homo- and hetero-dimerization with other family 
members. This dimerization enables EGFR auto-phosphoryl-
ation, which results in the recruitment of signaling proteins 
to the receptor culminating in cell proliferation and surviv-
al. ErbB activates the RAS/RAF/mitogen-activated protein 
kinase/extracellular signal-regulated kinase (ERK) and AKT 
downstream effector pathways, culminating in cell prolifera-
tion and survival. Inhibitors of the ErbB receptors are current-
ly being explored in clinical trials for CCA, including afatinib 
(NCT01679405) [8], lapatinib (NCT00107536) [9], gefitinib 
(NCT02836847), and erlotinib (NCT00033462) [8,9].
However, there is still a poor current understanding of the 
differential expression of ErbB receptor family either in tis-
sues from CCA patients or in CCA cell lines [10]. The optimal 
response of chemotherapeutic drugs and specific target ErbB 
inhibitors is also not known, and particularly, the optimal 
combinations of chemotherapeutics and specific target ErbB 
inhibitors, or their synergistic effects and potential use in 
CCA cells. Here we aimed to identify the differential expres-
sion of the ErbB receptor family, and determine the efficacy 
of combining chemotherapeutic drugs with drugs targeting 
ErbB receptors family in CCA tissues and primary CCA cells, 
and CCA cells lines derived from patients who had OV infec-
tion.
   
Materials and Methods
1. Droplet digital polymerase chain reaction 
RNA was extracted and purified from surgically resected 
tumor, four primary CCA cell lines (CCA-UK5, CCA-UK6, 
CCA-UK7, and CCA-UK9) and patient-matched, histologi-
cally tumor-free resected margin as a control. One micro-
gram of total RNA was reverse transcribed using 500 ng 
Oligo-d(T) and 250 ng random primers and M-MLV reverse 
transcriptase (Takara Shuzo Co., Tokyo, Japan). One microlit-
er of the total 20 µL cDNA was added to 1 µL Taqman Probe 
(EGFR, Hs01076092; HER2, Hs01001580; HER3, Hs00176538; 
and HER4, Hs00955522), and 8 µL ddH2O with 10 µL drop-
let digital polymerase chain reaction (ddPCR) super mix for 
probes (Bio-Rad, Hemel Hempstead, UK). Droplets were 
generated by adding 20 to 70 µL Droplet generation oil (Bio-
Rad, Hemel Hempstead, UK) using a QX100 droplet gen-
erator (Bio-Rad, Hemel Hempstead, UK). Amplification was 
carried out using standard Taqman protocols (10-minute 
activation step, 95°C, 40 cycles of 30 seconds denaturation 
at 95°C, 1 minute annealing and elongation 60°C and final 
extension 98°C 10 minutes using a PCR thermal cycler (Bio-
Rad, Hemel Hempstead, UK). Samples were analyzed using 
QX100 droplet reader (Bio-Rad, Hemel Hempstead, UK).   
2. Immunohistochemistry 
Immunohistochemistry was used to examine expression of 
EGFR family receptors in CCA patient tissues from tumours 
with different etiologies (OV related in the Thai group and 
nonOV in the UK group). Formalin-fixed-paraffin-embedded 
(FFPE) tumor samples from thirty patients were retrieved 
from the Department of Pathology, Ramathibodi Hospital, 
Mahidol University and Department of Pathology, Rajavithi 
Hospital, Bangkok, Thailand, and thirty patients from the 
Department of Pathology, Nottingham Universities Hospi-
tal Trust, for immunohistochemistry assessment. The tissues 
were histologically confirmed as mass forming CCA by the 
two pathologists of each institute (NL, CS and AZ, AM). OV-
related CCA in Thai patients was diagnosed by the patient 
fulfilling one of these five criteria: (1) a history of previous 
positive stool examination for OV or its eggs; (2) identifica-
tion of OV or its eggs in stool or bile; (3) demonstration of a 
typical bead-like cholangiogram; (4) demonstration of dilat-
ed peripheral small intrahepatic bile ducts, compatible with 
biliary parasitic disease on sonography, computed tomogra-
phy or magnetic resonance image; and (5) histopathological 
evidence of OV in the hepatic resected specimen. Each case 
was tested using the following primary antibodies: anti-EG-
FR, anti-HER2, anti-HER3, and anti-HER4 antibodies. Serial 
5-µm-thick sections of FFPE tissue were cut for a standard 
method for immunohistochemical analysis. The immunore-
activity was scored based on membranous and/or cytoplas-
mic staining [11] compared to positive control, as follows: no 
staining or faint staining in < 10% of tumor cells; 1+, weak 
perceptible membranous staining in ≥ 10% of tumor cells; 2+, 
moderate complete membranous staining in ≥ 10% of tumor 
cells; 3+, strong complete membranous staining in ≥ 10% of 
tumor cells [12,13]. Reference positive control tissue was nor-
mal placenta (for EGFR), receptor positive breast cancer for 
HER2 and HER3 and normal liver for HER4.
3. CCA cell lines and cultures
Cell lines used in this study included human CCA cell lines 
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established from CCA tissue of Thai patients, HuCCA-1, 
KKU-M213, KKU-100, and KKU-M055 (obtained from the 
Japanese Cell Research Bank (HuCCA-1 [JCRB1657], KKU-
M213 [JCRB1557], KKU-100 [JCRB1568], and KKU-M055 
[JCRB1551]), and a normal cholangiocyte cell line, MMNK-1 
[14,15]. All cell lines were cultured in RPMI supplemented 
with 10% fetal bovine serum and 2 mM L-glutamine (Sig-
ma-Aldrich, Dorset, UK) in 5% CO2 atmosphere at 37°C. 
KKU-M213 cells harbor mutations of KRAS (p.G13C), TP53 
(p.V31I), ERBB2 (p.N125D), and KKU-100 cells harbor 
mutations of KRAS (p.G12D) and TP53 (p.P72R). There is no 
mutation data for HuCCA-1 and KKU-M055. Mutation pro-
file of CCA cell lines (the DepMap portal website; https://
depmap.org/portal/cell_line/ACH-001538?tab=mutation; 
DepMap ID no. ACH-001538).
4. Western blot analysis 
ErbB protein expression was examined in CCA cell lines. 
Protein extracted using NP-40 lysis buffer containing 1% 
(vol/vol) Triton X (Calbiochem, Darmstadt, Germany), 1× 
protease inhibitor (Roche, Mannheim, Germany), 50 mM 
NaF (Sigma-Aldrich, St. Louis, MO), 2 mM sodium orthova-
nadate (Sigma-Aldrich, Dorset, UK) and phenylmethylsul-
phonyl fluoride (Sigma-Aldrich) and quantified using Pierce 
BCA Assay Kit (Thermo Scientific, Basingstoke, UK). Twen-
ty-five micrograms of protein was separated via sodium 
dodecyl sulfate polyacrylamide gel electrophoresis on 10% 
gels followed by wet transfer of the proteins to a nitrocel-
lulose membrane using Bio-Rad transfer equipment (Bio-
Rad, Hercules, CA), and transfer efficiency was confirmed 
by Ponceau S staining. The membranes were blocked in 5% 
BSA for 1.5 hours. Blots were then incubated with primary 
antibodies: anti-EGFR (Abcam, Cambridge, UK), anti-HER2, 
anti-HER3 (Cell Signaling Technology Inc., Beverly, MA), 
anti-HER4 (Abcam), and anti–α-tubulin antibodies (Cell 
Signaling Technology Inc.) at 4°C, overnight. The blots were 
then incubated with horseradish peroxidase–conjugated 
anti-rabbit or anti-mouse IgG secondary antibodies (Cell 
Signaling Technology Inc.) for 2 hours at room temperature 
and imaged using an Alliance Q9 mini Chemiluminescent 
gel imager (UVITEC, Cambridge, UK). The relative inten-
sity of the protein band was quantified by ImageJ (from NIH 
website by Scion Corporation, Frederick, MD) and Image 
Studio (LI-COR).
5. Chemotherapeutic drugs and ErbB inhibitors
Chemotherapeutic drugs used in this study included gem-
citabine, cisplatin, and 5-fluorouracil (5-FU). The specific 
ErbB inhibitors included afatinib, lapatinib, and erlotinib, 
all were purchased from Selleckchem (Houston, TX). The 
drugs were dissolved in cell culture grade dimethyl sulfox-
ide (DMSO) (AppliChem, Barcelona, Spain). Frozen DMSO 
stocks were prepared together with the drug to be used as 
vehicle. For cell lines, all drug treatments were performed at 
60%-80% cell confluence. 
6. Patient specimens and establishing close-to-patient 3D-
tumor growth assay 
Fresh surgical material from tumor resections at Notting-
ham University NHS Trust, was immediately placed into 
tissue transfer media (Dulbecco’s modified Eagle’s medium 
with 10% fetal bovine serum, 1% 0.2 M L-glutamate, 1% pen-
icillin/streptomycin/amphotericin B, 0.1% 1 mg/mL hydro- 
cortisone, 0.75% 1 mg/mL insulin) at 4°C, and processed 
within 4-6 hours. The majority of tissue was finely minced 
for immediate use and further portions were FFPE for 
immunohistochemistry, or stored in RNAlater (Ambion, 
Austin, TX) for subsequent analysis. 
In vitro tumor cell growth was established from five pati-
ents, four of which we went on to investigate drug sensi-
tivities (CCA-UK5, CCA-UK6, CCA-UK7, and CCA-UK9), 
and expanded with a layer of supporting feeder layer cells 
according to the method of Liu et al. [16] and as previously 
described by Saunders et al. [17]. A small amount of finely 
minced tumor tissue was enzymatically disaggregated by 
type II collagenase (100 U/mL, Invitrogen, Burlington, Can-
ada) and dispase (2.4 U/mL, Invitrogen) in Hank’s balanced 
salt solution without calcium or magnesium (Sigma-Aldrich, 
Dorset, UK) at 37°C under constant rotation. Cells were 
removed at hourly intervals until the tumor was completely 
disaggregated. Cells were allowed to settle on the feeder lay-
er, and expanded. If fibroblasts (assumed cancer associated 
fibroblasts [CAFs]) were seen amongst the epithelial popu-
lation, they were harvested using differential trypsinisation, 
and subsequently grown separately. Cell number and viabil-
ity were determined using trypan blue exclusion.
The CCA cells were harvested and employed for close-
to-patient three-dimensional tumor growth assays. Briefly, 
cells were resuspended in 9 mg/mL ice-cold Cultrex base-
ment membrane extract (Trevigen, Gaithersburg, MD), 
diluted in modified RPMI-1640 containing phenol red-free 
and 6 mmol/L D-Glucose at pH 6.8) (Life Technologies, Inc., 
Rockville, MD). CCA cells (confirmed by human-specific 
antibodies) were suspended in basal membrane extract in the 
presence or absence of the CAFs or human bone-marrow- 
derived mesenchymal stem cells (MSCs, Sciencell, UK). Cells 
were then plated into low adherent, black-walled, clear bot-
tom 384-well plates at 6,250 tumor cells±CAFs/MSCs. Drugs 
at 0.1, 1, 10, and 100 µM were added in six replicates on day 
3. Drugs used in combination were premixed and serially 
diluted together before adding to the assay. Drug exposure 
was for 96 hours before final endpoint readings. An Alamar-
Boonyakorn Boonsri, EGFR Inhibitors in Cholangiocarcinoma
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Blue assay (Invitrogen); 10% (v/v) was added for 1 hour at 
37°C to monitor cell growth daily using fluorescent plate read-
er (FLUOstar Omega, BMG Labtech). Drug sensitivity was 
calculated as a percentage of a matched untreated control and 
IC50 were determined using GraphPad Prism 8 (GraphPad 
Software, Inc., La Jolla, CA), nonlinear curve fit of y=100/(1+ 
10(Log1C50-X)×HillSlope). 
7. Cell growth inhibition assay 
The proliferative effect of specific ErbB tyrosine kinase 
inhibitors (afatinib, lapatinib, and erlotinib) (Selleckchem) on 
human CCA cells was determined by MTT assay. In brief, 
CCA cells (HuCCA-1, KKU-M213, KKU-100, and KKU-
M055) were grown overnight in 96-well plates at density 
of 5×103 cells/well, then incubated with different concen-
trations of specific ErbB tyrosine kinase inhibitors (0.1, 1, 
and 10 µM) for 48 hours. Cells (HuCCA-1 and KKU-M213) 
were also incubated with the chemotherapeutic drugs: gem-
citabine, cisplatin, 5-FU (Selleckchem) at 0.1, 1, and 10 µM 
for 48 hours. Cells without drug treatment were used as a 
control group and 0.1% DMSO treated cells were used as a 
vehicle control group. After incubation, 100 µL of MTT solu-
tion (0.5 mg/mL, Sigma-Aldrich, St. Louis, MO) was added 
to each well and incubated for a further 4 hours at 37°C in 
the dark. Subsequently, 100 µL of DMSO (Merck, Darm-
stadt, Germany) was added to each well and absorbance 
of the sample was measured at OD490 nm by a Versamax 
microplate reader using SoftMax Pro 4.8 analysis software 
(Molecular Devices, San Jose, CA). The IC50 value was calcu-
lated based on the nonlinear regression curve fit method by 
GraphPad Prism 6.0 software (GraphPad Software, Inc.). The 
greatest best-fit curve was used for calculation and R2 value 
was more than 0.8. 
8. Drug combination treatment and combination index 
The drug combination study was performed in HuCCA-1 
and KKU-M213 cells by using a fixed concentration of gem-
citabine (0.1 µM) combined with cisplatin, 5-FU, or with spe-
cific ErbB inhibitors (afatinib, lapatinib, and erlotinib) at 0.1, 
1, and 10 µM. Interactions between the different drugs were 
evaluated using the combination index (CI) as described by 
Chou [18]. The CI for each fraction-affected value (Fa-CI) 
representing the percentage of proliferation inhibited by a 
drug. A plot of CI values and Fa-CI for each drug-pair was 
generated using the CompuSyn software (ComboSyn, Inc., 
Paramus, NJ; available for free download from http://www.
combosyn.com. A CI interpreted as: CI value < 1.0, synergis-
tic; 1.0, additive and > 1.0, antagonistic. 
9. Cell cycle analysis
Cell cycle distribution was analyzed using flow cytometry. 
HuCCA-1 and KKU-M213 cells were cultured and starved 
with serum-free media overnight. Cells were treated with 
a single treatment of gemcitabine (0.1 µM) or afatinib (0.1 
µM) for 24 hours. Concurrent treatment with gemcitabine 
and afatinib (G+A) and sequential treatments of gemcitabine 
(6 hours) followed with afatinib (18 hours) (G→A) and an 
inverted order with the same interval (A→G) were also per-
formed. Cells were harvested and prepared for flow cytom-
etry by incubated with propidium iodide (Sigma-Aldrich, 
St. Louis, MO). DNA content of cells was determined using 
a flow cytometer (BD FACSCanto model, BD Biosciences). 
The protein samples were applied to western blotting and 
incubated with the following primary antibodies: anti-cyclin 
D1, anti-cyclin E (Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA), and anti α-tubulin antibodies (Cell Signaling Technol-
ogy Inc.). 
10. Statistical analysis 
Experiments were performed in triplicate. Data are pre-
sented as means±standard error of mean and statistically 
analyzed using GraphPad Prism program ver. 6 (GraphPad 
Software, Inc.) by one-way ANOVA followed by Tukey’s 
multiple comparison tests and within-treatment group com-
parisons were performed using paired t test (2-tailed). Dif-
ference with p-values less than 0.05 were considered statisti-
cally significant.
Results
1. Expression of ErbB receptor family in CCA tissues 
mRNA expression of ErbB receptors by ddPCR revealed 
high expression of EGFR, HER2 HER3, and HER4 (Fig. 1A) 
in tumor tissues compared with tissue resection margin, and 
in tumor cells isolated from primary tissues compared with 
normal cells isolated from the margin (Fig. 1B). Immuno-
histochemistry of all tissue sections from both OV positive 
patients from Thailand and presumed OV negative patients 
from the UK patients (compared due to different etiologies) 
were positive for all ErbB family receptors; however, they 
showed different intensities (Table 1, Fig. 1). Immunoreac-
tive staining intensity was scored relative to that of a refer-
ence positive control. Compared with histologically normal 
tissues taken from the resection margin of the CCA all ErbB 
receptors had expression that was more intense in tumor 
cells from CCA patients from both Thailand and the UK 
(Fig. 1C). All CCA cases showed positive staining for EGFR 
with most showing moderate or strong staining (Table 1). 
CCA tissues from both Thailand and the UK were weakly 
to moderately stained for HER2 (Table 1). HER3 was weak-
ly stained in both Thailand and the UK CCA tissues. HER4 
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was strongly stained in Thailand and the UK tumors. Nota-
bly, these findings highlighted that EGFR, HER2, and HER4 
are highly expressed in CCA tumors irrespective of whether 
they come from - UK patients not exposed to OV, or from 
fluke-induced Thai cancers. We confirmed that the high 
expression of ErbB was preserved in immortalized CCA 
cell lines (S1A Fig.). ErbB expression was investigated in 4 
CCA cell lines derived from patients with CCA associated 
with fluke infection including KKU-M213, HuCCA-1, KKU-
100, and KKU-M05 and a cholangiocyte cell line, MMNK-1. 
Immunoblotting showed that KKU-M055 cells expressed low 
levels of all the ErbB receptors while KKU-M213, HuCCA-1, 
and KKU-100 cells highly expressed EGFR, HER2, and HER3 
proteins (S1B Fig.). The relative expression levels of EGFR, 
HER2, and HER3 proteins were found to be HuCCA-1 > 
KKU-M213 > KKU-100 > KKU-M055 while for HER4 this 
was HuCCA-1 > KKU-M213 > KKU-M055 and KKU-M100. 
We also determined mRNA expression of ErbB at transcrip-
tion level and found that the mRNA transcript of EGFR and 
its family members, HER2, HER3, and HER4 in these CCA 
cell lines were not consistent with the protein expression, 
while all ErbB receptors were equally expressed in MMNK-1 
cells (S1D Fig.). 
2. Sensitivity of CCA cells to treatment with specific ErbB 
tyrosine kinase inhibitors and chemotherapeutic drugs 
We then investigated the effects of ErbB inhibitors on the 
growth of CCA cell lines. All three inhibitors (afatinib, lapat-
inib, and erlotinib) were cytotoxic in a dose-dependent man-
ner (Fig. 2A-C) with IC50 values ranging from 0.31-23.65 µM 
(Table 2). The HuCCA-1 cells were the most sensitive to all 
drug treatments: afatinib (IC50=0.73 µM), lapatinib (IC50=0.32 
Boonyakorn Boonsri, EGFR Inhibitors in Cholangiocarcinoma
Fig. 1.  Expression of ErbB receptors in surgically resected patient cholangiocarcinoma (CCA) tissue. (A) Absolute RNA expression of 
epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER) 2, HER3, and HER4 transcript levels in paired 
CCA patient resected tissue and adjacent margin, detected by droplet digital polymerase chain reaction (ddPCR). Significant difference 
was determined by paired t test. (B) Absolute expression of EGFR, HER2, HER3, and HER4 transcript levels in primary CCA cells isolated 
from the tumor tissue and primary cells from normal tissue margins, detected by ddPCR. Significant difference was determined by Welch’s 
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µM), and erlotinib (IC50=4.52 µM). KKU-M213 exhibited the 
least sensitivity to all drugs: afatinib (IC50=4.31 µM), erlotinib 
(IC50=8.06 µM), and lapatinib (IC50=11.14 µM). There was no 
apparent correlation between the response to the treatments 
of ErbB inhibitors (IC50 values) and the expression of ErbB 
proteins (S2 Fig.). The most sensitive HuCCA-1 cells and 
the least sensitive KKU-M213 cells were selected for further 
experiments.
3. Effect of combined treatment of ErbB inhibitors with 
gemcitabine in HuCCA-1 and KKU-M213 cells 
To determine whether ErbB inhibitors could in addition to 
existing therapies we examined the effect of ErbB2 inhibitors 
in the presence of effective cytotoxic agents. We first con-
firmed the sensitivity of HuCCA-1 and KKU-M213 cells to 
chemotherapeutic drugs (gemcitabine, cisplatin, and 5-FU). 
This confirmed that HuCCA-1 cells were more sensitive to 
Cancer Res Treat. 2020 Oct 7 [Epub ahead of print] 
Fig. 1.  (Continued from the previous page) (C) Immunohistochemistry for ErbB proteins in CCA tissues. EGFR: placenta (positive control 
EGFR); breast cancer (positive control HER2 and HER3) and normal liver (positive control HER4). Immunopositive cells stained with 





Thai tumour UK tumour Positive control
HER3
HER4
Table 1.  Percentage of ErbB stained tumor from the UK and Thai patients
EGFR family Origin
  Immunohistochemistry  
p-value
  Weak Moderate Strong
EGFR  UK 13.3 53.3 33.3 0.430
 Thai 26.7 46.7 26.7 
HER2  UK 60 40 0 0.027
 Thai 40 40 20 
HER3  UK 80 20 0 0.206
 Thai 80 13.3 6.7 
HER4  UK 0 20 80 0.061
 Thai 6.7 40 53.3 
Values are presented as percentage. EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor. 
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gemcitabine than (IC50=0.76 µM) 5-FU (IC50=4.64 µM), or cis-
platin (18 µM) (S3A Fig.) while KKU-M213 showed less sen-
sitivity to all three drugs: gemcitabine (IC50=14.73 µM), 5-FU 
(IC50=15.68 µM) and cisplatin (16 µM) (S3B Fig.). We further 
determined the interaction effect of combining gemcitabine 
with cisplatin or gemcitabine with 5-FU. There was an antag-
onistic effect of adding cisplatin to gemcitabine in HuCCA-1 
(S3C Fig.), and KKU-M213 cells (S3D Fig.) with the comput-
ed CI values > 1 (S3E and S3F Fig.), whereas, gemcitabine 
(0.1 µM) combined with 5-FU (0.1, 1, and 10 µM) showed a 
significant additive effect on growth inhibition in both cell 
lines in a dose-dependent manner (S3C and S3D Fig.), with 
the computed CI values < 1 (S3E and S3F Fig.).
As gemcitabine seemed the most likely to provide addi-
tional benefit, we therefore determined the effect of gem-
citabine combination with tyrosine kinase ErbB inhibitors 
(afatinib, lapatinib, and erlotinib) at a fixed ratio (0.1: 0.1, 1, 
10 µM) and the efficacy of combination treatment was evalu-
ated in the least and most sensitive cell lines (KKU-M213 
and HuCCA-1). In HuCCA-1 cells, a synergistic effect was 
Boonyakorn Boonsri, EGFR Inhibitors in Cholangiocarcinoma
Fig. 2.  The percentage of cell survival of different four cholangiocarcinoma cell lines treated with various concentrations of ErbB inhibitors 
at 48 hours by MTT assay. Afatinib (A), lapatinib (B), and erlotinib (C). The percentage cell survival of the combined treatments of fixed 
concentration of gemcitabine (0.1 μM) with afatinib, lapatinib, and erlotinib (0.1, 1, and 10 μM) in HuCCA-1 cells (D) and KKU-M213 (E).  
*p < 0.05 compared with untreated control group, #p < 0.05 compared with the gemcitabine-treated group The combination effect is  








































































































































































































Table 2.  IC50 value (µM) of the specific ErbB inhibitors at 48 
hours
 CCA cell line 
 IC50 at 48 hr (µM) 
 Afatinib Erlotinib Lapatinib
KKU-M213 (JCRB1557) 4.305 8.058 11.140
HuCCA-1 (JCRB1657) 0.729 4.519 0.3237
KKU-100 (JCRB1568) 1.609 7.948 0.3074
KKU-M055 (JCRB1551) 3.823 23.65 3.892
 CCA, cholangiocarcinoma.
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observed when afatinib (0.1, 1, and 10 µM), lapatinib (10 µM), 
or erlotinib (10 µM) were combined with 0.1 µM gemcitabine 
compared to gemcitabine alone (Fig. 2D). In KKU-M213, a 
synergistic effect was observed when afatinib (0.1, 1, and 
10 µM) or erlotinib (1 and 10 µM) was combined with 0.1 
µM gemcitabine while gemcitabine combined with lapatinib 
showed no beneficial effect (Fig. 2E). Combined treatment 
of gemcitabine with either afatinib or erlotinib showed a CI 
value toward synergism in both HuCCA-1 (S4A Fig.) and 
KKU-M213 cells (S4B Fig.). In contrast, the combined treat-
ment of gemcitabine and lapatinib mostly produced antago-
nistic effect (very high CI values) (S4A and S4B Fig.). These 
results indicated that the growth inhibitory effect of gemcit-
abine was enhanced by the addition of afatinib and erlotinib 
but not lapatinib. 
We chose afatinib to further investigate a synergistic effect 
of the combined treatments using three different approaches: 
(1) concurrent treatment of gemcitabine (0.1 µM) with afatin-
ib for 24 hours (G+A), (2) sequential treatment of gemcitabine 
(6 hours) followed with afatinib for 18 hours (G→A) and (3) 
inverted treatment with afatinib then gemcitabine (A→G) 
with the same interval (Fig. 3). Cells were also treated with 
gemcitabine alone (0.1 µM) or afatinib alone (0.1, 1, or 10 µM) 
for comparison. The results demonstrated that a single treat-
ment of gemcitabine for 24 hours at 0.1 µM slightly decreased 
cells viability while afatinib at 1 and 10 µM significantly de-
creased viability of both HuCCA1 (Fig. 3A) and KKU-M213 
cells (Fig. 3B). For HuCCA1 cells, only a concurrent treat-
ment of 0.1 µM gemcitabine and 0.1 µM afatinib showed a 
beneficial additive effect compared to their respective dose 
of afatinib; however, growth inhibition was small. Increas-
ing the concentration of afatinib did not enhance the additive 
effect. Sequential treatment (G→A) showed an additive 
effect to 0.1 µM afatinib alone. While an additive effect for 
inverted treatment (A→G) was observed using afatinib at 0.1 
and 1 µM. Moreover, the sequential treatment using 0.1 µM 
afatinib with gemcitabine in both G→A and A→G showed 
similar levels of growth inhibition (Fig. 3A). For KKU-M213 
cells, all concurrent treatments of gemcitabine and afatinib 
showed no additive effect to afatinib. Additive effect was 
followed with 0.1 µM afatinib (G→A) and the reverted order 
(A→G) at afatinib 0.1 and 1 µM (Fig. 3B).
4. Effect of gemcitabine and afatinib combination treat-
ment on cell cycle  
We performed cell cycle analysis to determine whether 
the result of the synergistic effect of gemcitabine combined 
with afatinib resulted from cell cycle arrest or apoptosis. 
The cell cycle distribution of HuCCA-1 and KKU-M213 cells 
after single drug treatment, concurrent or sequential treat-
ments of gemcitabine (0.1 µM) and afatinib (0.1 µM) for 24 
hours are shown in Fig. 4. Treatment of HuCCA-1 cells with 
gemcitabine alone increased cells accumulated in the subG1 
(apoptotic/dead cells) and S phases consistent with inhibi- 
tion of DNA synthesis, and this was associated with 
decreased cell viability (Fig. 4A) while with afatinib treat-
ment alone, cells accumulated in subG1 phase. Concurrent 
treatment of gemcitabine and afatinib (G+A) increased cell 
accumulation in S phase. Both sequential treatments of G→A 
and A→G induced accumulation in the subG1 and S phases, 
accompanied by decreased cells in G2/M phase compared to 
control (Fig. 4A). 
For KKU-M213 cells, either gemcitabine or afatinib single 
treatment showed no significant effect on cell cycle distribu-
Cancer Res Treat. 2020 Oct 7 [Epub ahead of print] 
Fig. 3.  The percentage cell survival of HuCCA-1 (A) and KKU-M213 (B) cells treatment with gemcitabine (0.1 μM), afatinib (0.1 μM blue, 
1 μM red, 10 μM green), concurrent treatment of gemcitabine (0.1 μM) and afatinib (0.1, 1, and 10 μM), sequential treatment of gemcit-
abine (0.1 μM) (6 hours) followed with afatinib (0.1, 1, and 10 μM) (18 hours) and sequential treatment of afatinib (0.1, 1, and 10 μM)  
(6 hours) followed with gemcitabine (0.1 μM) (18 hours) of survival. *p < 0.05 compared with untreated control group, #p < 0.05 compared 
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Fig. 4.  Effect of gemcitabine and afatinib combination on cell cycle distribution in HuCCA-1 (A) and KKU-M213 (B) cells. Representative 
Western blotting showing the expression of cyclin D1 and cyclin E proteins in HuCCA-1 (C) and KKU-M213 (F) cells treated with gemcit-
abine (0.1 μM), afatinib (0.1 μM), concurrent treatment of gemcitabine and afatinib (G+A), sequential treatment of gemcitabine (6 hours) 
followed with afatinib (18 hours) (G→A) and sequential treatment of afatinib (6 hours) followed with gemcitabine (18 hours) (A→G). 
Corresponded densitometric analysis of cyclin D1 (D, G) and cyclin E (E, H) proteins expression normalized with α-tubulin in HuCCA-1 
and KKU-M213 cells, respectively. Expression value is expressed as fold of control (mean±standard error of mean) from three independent 
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tion compared to untreated control cells. Concurrent treat-
ment of gemcitabine and afatinib significantly increased cells 
in subG1 population associated with a decrease in G0/G1 
and S phases. Sequential treatments of either G→A or A→G 
significantly increased cells accumulation in S phase (Fig. 
4B). These results support the hypothesis that concurrent 
treatment forced the majority of cells to undergo cell death 
while sequential treatment resulted in S-phase arrest.
We next determined the expression of cyclin D1 and cyc-
lin E cell cycle regulators. Western blot analysis showed that 
treatment with gemcitabine had no effect on cyclin D1 but 
upregulated cyclin E in HuCCA-1 cells (Fig. 4C-E). Afatinib 
single treatment slightly decreased levels of cyclin D1 in both 
HuCCA-1 (Fig. 4C and D) and KKU-M213 cells (Fig. 4F and 
G). The combination treatments of gemcitabine and afatinib 
(G+A, G→A, A→G) significantly decreased expression of 
cyclin D1 (Fig. 4C, D, F, and G) but not cyclin E compared 
to control and gemcitabine alone in both cells (Fig. 4C, E, F, 
and H).
5. Sensitivity of ErbB inhibitors in primary CCA cells
We next assessed the response to ErbB inhibitors in pri-
mary CCA cells isolated from patients, in a 3D setting, in the 
presence of either CAFs or MSCs (Fig. 5A). Cells were grown 
in 3D 96 well plates, and then treated after growth and cell 
survival measured (Fig. 5B). While all four cell lines tested 
showed a sensitivity to gemcitabine/cisplatin treatment that 
was below the mean peak serum concentration (mPSC) for 
Cancer Res Treat. 2020 Oct 7 [Epub ahead of print] 
Fig. 5.  Effect of ErbB inhibitors on primary cholangiocarcinoma (CCA) lines in 3D-tumor growth assay (TGA). (A) Four primary cells were 
derived from surgically resected CCA tissue samples; CCA-UK5, CCA-UK6, CCA-UK7, and CCA-UK9. Primary cells (dashed), matched 
cancer associated fibroblasts (CAFs) also derived from the same tissue samples (solid), a human mesenchymal cell line (mesenchymal stem 
cell [MSC] not shown) or a mixture (CAF+cancer cells shown as dotted line) were employed for the 3D-TGA. (B) Growth of cells, CAFs, 
and primary cells and CAF (red line) or MSC (green line) mixed with the primary cells was measured using AlamarBlue. Percent cell 
survival of CCA1 and CCA2 treated with gemcitabine/cisplatin (Gem/Cis) (C), erlotinib (D), or afatinib (E). The mean±20% peak serum 
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patients undergoing treatment with these agents, the addi-
tion of CAFs or MSCs increased the resistance to these treat-
ments, and in two cases to above the mPSC, indicating that 
while cells from these two tumors might appear to be sen-
sitive on their own, one would predict that they would be 
insensitive to treatment clinically (Fig. 5C). When cells were 
treated with erlotinib, they appeared to be borderline sensi-
tive or insensitive by themselves, and addition of CAFs or 
MSCs made them much less sensitive (i.e., resistant) to erlo-
tinib treatment (Fig. 5D). In contrast, all four cell types were 
sensitive (IC50 less than or equal to the mPSC) for Afatinib, 
and three of the four were highly sensitive (IC50 less than 
80% of the mPSC) in the presence of CAFs, and all four were 
highly sensitive in the presence of MSCs (Fig. 5E). These 
results suggest that not only are primary CCA cells sensitive 
to afatinib, they are potentially more so in a tumor relevant 
setting (in the presence of other stromal cells).
Discussion
In this study, we show that CCA cells, a very aggressive 
malignant biliary epithelial cell transformation, resistant to 
chemotherapy both in vivo and in vitro [19] are highly sensi-
tive to some ErbB inhibitors. We provide evidence that the 
panEGFR-TK inhibitor afatinib is a promising treatment in 
CCA alone or in combination with gemcitabine. We also 
show the expression level of ErbB family in UK and Thai 
CCA tissues, UK primary cells, and different Thai CCA cell 
lines. Our study showed that CCA tissues from IHCC pati-
ents highly expressed EGFR, HER2, HER3, and HER4 from 
weak to strong levels. All ErbB receptors were consistently 
highly expressed in primary CCA cells and CCA cell lines. 
Two of four cell lines highly expressed EGFR, HER2, and 
HER3. One cell line HuCCA-1 cells also highly expressed 
HER4. Our results are consistent with a previous study by 
Yang et al. [20]; however, their cohorts study revealed HER2 
was strictly expressed in extrahepatic CCA. Interestingly the 
expression pattern was remarkably consistent between the 
Thai and UK groups—despite differences in etiology (the 
presence of OV infection as a risk factor) and likely ethnic 
differences (although ethnicity data was not collected from 
the UK or Thai patients, the influence of ethnicity is likely to 
be minimal relative to the difference in etiology). 
We investigated the growth response of a panel of CCA 
cell lines to treatment with ErbB inhibitors: afatinib, lapat-
inib, and erlotinib. There was no correlation of the ErbB 
expression with IC50 of drugs that target ErbB. Others have 
also reported a lack of a close correlation between varying 
degrees of EGFR expression in tumor cells and their sensi-
tivity to EGFR tyrosine kinase inhibitor (TKI) inhibitors [6]. 
Additionally, there was no statistically significant associa-
tion between EGFR or HER2 expression and the anti-tumor 
effect of the dual EGFR/HER-2 TKI lapatinib [21]. These 
findings suggest that ErbB receptor expression levels are not 
likely to be useful as predictive biomarkers to identify a drug 
response in vitro. 
Of the four CCA cell lines, two high ErbB proteins express-
ing CCA cell lines showed different sensitivity to all the 
drugs tested, HuCCA-1 cells showed the greatest growth-
inhibiting activity (low IC50) while KKU-M213 cells showed 
the least sensitivity (high IC50). We found no apparent cor-
relation between the response to the treatments of ErbB 
inhibitors and the expression of ErbB proteins. These suggest 
that in CCA cells level of ErbB receptor expression per se is 
not a relevant marker of drug response. Other factors such as 
the mutation status of ErbB receptors or their activation sta-
tus, using molecules such as KRAS and TP53 may instead be 
important. Difference in sensitivity to ErbB targeted drugs 
may be due to difference in mutation status of the two cell 
lines. KKU-M213 cells harbor KRAS, ERBB2, and TP53 
mutants and showed less sensitive to both specific ErbB 
inhibitors and chemotherapeutic drugs. This evidence was 
supported by previous studies that reported that the treat-
ment outcome of KRAS mutation-positive biliary tract can-
cer patients was significantly worse than that of KRAS wild-
type patients [22], and point mutations of KRAS are usually 
associated with the onset of acquired resistance to anti-EGFR 
treatment [23]. In addition, TP53 mutation has been reported 
to be a negative factor for the outcome of patients with TKI 
therapy [24] and chemotherapeutic drugs including gemcit-
abine, cisplatin, and 5-FU [25,26]. Unfortunately, there is no 
data on mutation status of HuCCA-1 cell. 
As expected, the sensitivity of these two cell lines to chem-
otherapeutic drugs was different; HuCCA-1 cells were more 
sensitive to gemcitabine while KKU-M213 cells were less 
sensitive to all tested chemotherapeutic drugs. Afatinib is an 
oral, irreversible ErbB family blocker that covalently binds 
to the kinase domains of EGFR, HER2, and HER4, resulting 
in irreversible inhibition of tyrosine kinase autophosphoryla-
tion. Afatinib was found to show a superior progression-free 
survival over gefitinib or erlotinib in non-small cell lung can-
cer [27]. We therefore evaluated the efficacy on growth inhi-
bition of the concurrent and sequential combination of fixed 
ratio of gemcitabine with rising concentrations of afatinib 
compared with single treatment. We found an additive effect 
over the single treatment of afatinib or gemcitabine (at the 
respective dose) when cells were sequentially treated by low 
dose of afatinib (100 nM) in both (G→A) or inverted order 
(A→G) and these corresponded to a CI value that equates to 
synergism. 
Cell response to a drug comprises a complex sequence of 
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events; some die, some do not proliferate. Here, we exam-
ined if the additive effect resulted from alteration of the event 
in cell cycle. As observed in other cancer cells, the sensitive 
cells HuCCA-1 treated with gemcitabine (100 nM) alone 
induced increased subG1 and S and decreased G0/G1 cell 
population. This event was associated with upregulating 
of cyclin E, a regulator of cyclin-dependent protein kinases, 
which mediates the cell cycle transition from G1 to S phase 
[28]. Similar to other reports, afatinib alone inhibited growth 
of HuCCA-1 through G1 arrest and apoptotic cell death, 
which was associated with a decrease in cyclin D1 expres-
sion. The cell cycle events in concurrent treatment G+A in 
HuCCA-1 were similar to that of gemcitabine treatment 
alone. Along with a slight decrease in cell viability, it sug-
gests that 100 nM afatinib concurrently treated with gem-
citabine did not provide an additional effect to gemcitabine. 
These results are not inconsistent with a recent clinical trial 
by Moehler et al. [8], in which afatinib failed to show survival 
benefits in combination with continuing gemcitabine/cispl-
atin in nine patients who had progressed on gemcitabine/
cisplatin with advanced CCA in a phase I trial. They sug-
gested that chemotherapy drugs mainly act on cells in the 
proliferating and division phase; therefore, concurrent appli-
cation of small molecule inhibitors and chemotherapy drugs 
might not be an appropriate treatment schedule to achieve 
synergism efficiency. This evidence suggests an important of 
timeframe schedule of the combined treatments.
In sequential treatment (G→A), more cells died (increased 
SubG1) and cells arrested in S phase. The low concentration 
of gemcitabine could allow viable cells in S phase to be res-
ponsive to afatinib. Thus, potentiation of the effects on cells 
traversing S phase may lead to the synergism. Similar results 
were found in a sequential administration of pemetrexed 
followed by erlotinib for non-small cell lung cancer [29]. In 
the inverted order (A→G) however, the cell cycle measure-
ments suggest that this treatment sequence enabled some 
cells to overcome the G1 block by afatinib, but then become 
sensitized to gemcitabine resulting in an additive outcome 
in HuCCA-1 cells. These results are in agreement with the 
previous studies which reported that pre-treatment with low 
doses of kinase inhibitors can sensitize cancer cells to chemo-
therapy and simultaneously arrest the growth in normal 
cells, protecting them from subsequent chemotherapy [30]. 
KKU-M213 cells were resistant to afatinib treatment, possible 
due to the cells harboring TP53 mutation since the wild-type 
p53 is known to promote G0/G1 arrest [31]. However, when 
cells treated with the sequential G→A and A→G treatments, 
more cells died, and cells were reinforced to S phase arrest. 
Interestingly, cyclin D1 was only downregulated by the com-
bination of afatinib and gemcitabine. This indicates that this 
combination can reduce progression through G1 phase of 
the cell cycle. Cyclin D1 is a regulatory subunit of CDK4 and 
CDK6, which have recently been shown to be required for 
CCA progression, through a transcriptional activator PTH/
HHEX [32]. The results described here suggest that afatinib 
in combination with gemcitabine could add in additional 
therapeutic options for CDK4/6 resistant cancers. Overall, 
these results indicated that sequential treatments of gemcit-
abine and afatinib in either order produced additive growth 
inhibition effect to gemcitabine and afatinib in both gemcit-
abine sensitive and insensitive CCA cells. The mechanism 
of the synergism is still unknown, and genomic profiling of 
these cells could help to understand that.
We also show that the combined treatment of gemcitabine 
with 5-FU had a growth inhibition effect over either combi-
nation gemcitabine/cisplatin or each drug monotherapy in 
both HuCCA-1 and KKU-M213 cells. This finding provides 
a rationale for further clinical studies of chemotherapy treat-
ment of the gemcitabine and 5-FU combination in Thai CCA 
patients. 
Finally, we showed that in 3D culture, the presence of 
fibroblasts has a significant impact on the sensitivity to 
standard chemotherapies, but insufficient effect on erlotinib 
to suggest likely efficacy in vivo (as previously shown where 
erlotinib did not inhibit tumor growth in mice [33]). The use 
of close-to-patient models (primary derived cells) in combi-
nation with CAFs or their equivalent provides a more clini-
cally relevant test of drug efficacy than using immortalized 
cell lines that have been grown for years on plastic and will 
have drifted substantially from their parental origin. It has 
been clearly shown that cancer cells directly derived from 
patients are more closely phenotypically and genotypically 
related than cell lines and that their behaviour in the pres-
ence of CAFs reflects more closely what happens in the tumor 
microenvironment [17]. Interestingly, the presence of CAFs 
in 3D culture enhanced the afatinib response effect suggest-
ing that this could have an effect in mice or potentially in 
humans. It is noted that these primary human CCA-derived 
cancer cells were taken from UK patients, which may have a 
different response to Thai CCA cells. Thus, a comparison of 
3D tumor growth assays on Thai patients’ cells would be of 
interest if such primary cell cultures could be initiated. There 
is evidence that primary cancer cells co-cultured with prima-
ry CAFs/MSCs have more likelihood of translation through 
to in vivo mouse and human studies than primary cancer 
cells themselves. It is interesting that in spite that almost 
all evidence published up to date indicating that fibroblast, 
and more specifically CAFs, contribute to the chemoresist-
ance of tumor cells in many types of cancer, including CCA, 
our finding showed the complete opposite effect for afatinib. 
This might be consistent with recent observations in geneti-
cally engineered mouse models and clinical studies that have 
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suggested that CAFs are not one entity but rather contain 
heterogeneous functional subpopulations. There may exist at 
least two functionally different populations of CAFs, includ-
ing cancer-promoting CAFs, cancer-restraining CAFs. 
In conclusion, we demonstrated the potential therapeutic 
benefits of afatinib in combination with gemcitabine which 
exerted anti-tumor activity superior to each drug monother-
apy particularly in the KRAS-mutated CCA cells. Our results 
strengthen the concept that a sequential treatment schedule 
combining afatinib and gemcitabine may be important for 
improving outcome against CCA. 
Electronic Supplementary Material
Supplementary materials are available at Cancer Research and 
Treatment website (https://www.e-crt.org).
Ethical Statement 
Fresh surgical material from tumor resections at Nottingham Uni-
versity NHS Trust, were collected with informed patient consent 
and National Research Ethics Service approval (NRES REC 10/
H0405/6). Samples were used in accordance with NRES approval 
(NRES REC 08/H0403/37). The study protocol in Thailand was 
approved by the ethical clearance committee on human rights 
related to research involving human subjects, Faculty of Medicine 
Ramathibodi Hospital, Mahidol University (protocol no. 12-58-41) 
and Rajavithi Hospital (protocol no. 61042).
Author Contributions
Conceived and designed the analysis: Wongprasert K, Bates DO, 
Tohtong R, Janvilisri T, Kumkate S, Grabowska AM, Larbcharoen-
sub N.
Collected the data: Boonsri B, Yacqub-Usman K, Thintharua P, 
Myint KZ, Sae-Lao T, Collier P, Suriyonplengsaeng C, Egbuniwe IU.
Contributed data or analysis tools: Suriyonplengsaeng C, Kumkate 
S, Gomez D, Egbuniwe IU, Mukherjee A, Zaitoun AM, Kuakpae-
toon T.
Performed the analysis: Boonsri B, Yacqub-Usman K, Balasubrama-
nian B, Venkatraman S, Myint KZ, Thintharua P, Bates DO.
Wrote the paper: Boonsri B, Wongprasert K, Bates DO, Tohtong R, 
Yacqub-Usman K, Myint KZ, Venkatraman S, Balasubramanian B, 
Grabowska AM.
Conflicts of Interest
Conflicts of interest relevant to this article was not reported.
Acknowledgments
This work is supported by the Thailand Research Fund and the 
Medical Research Council (UK), Newton Fund MR/N01247X/1, 
Project Nos. DBG 5980006, Rajavithi Hospital Research Fund, 
“Young Researcher Development Program 2018” from National 
Research Council of Thailand (NRCT), and Research Assistantship, 
Faculty of Graduate Studies, Mahidol University. We would like to 
thank John Gordan for sharing cell lines.
Boonyakorn Boonsri, EGFR Inhibitors in Cholangiocarcinoma
1.  Konfortion J, Jack RH, Davies EA. Coverage of common can-
cer types in UK national newspapers: a content analysis. BMJ 
Open. 2014;4:e004677.
2.  Maroni L, Pierantonelli I, Banales JM, Benedetti A, Marzioni 
M. The significance of genetics for cholangiocarcinoma devel-
opment. Ann Transl Med. 2013;1:28.
3.  Sahu S, Sun W. Targeted therapy in biliary tract cancers-cur-
rent limitations and potentials in the future. J Gastrointest 
Oncol. 2017;8:324-36.
4.  Hyung J, Kim B, Yoo C, Kim KP, Jeong JH, Chang HM, et al. 
Clinical benefit of maintenance therapy for advanced biliary 
tract cancer patients showing no progression after first-line 
gemcitabine plus cisplatin. Cancer Res Treat. 2019;51:901-9.
5.  Ritter CA, Arteaga CL. The epidermal growth factor recep-
tor-tyrosine kinase: a promising therapeutic target in solid 
tumors. Semin Oncol. 2003;30(1 Suppl 1):3-11.
6.  Ciardiello F, Tortora G. A novel approach in the treatment of 
cancer: targeting the epidermal growth factor receptor. Clin 
Cancer Res. 2001;7:2958-70.
7.  Roskoski R Jr. ErbB/HER protein-tyrosine kinases: Structures 
and small molecule inhibitors. Pharmacol Res. 2014;87:42-59.
8.  Moehler M, Maderer A, Ehrlich A, Foerster F, Schad A, Nick-
olay T, et al. Safety and efficacy of afatinib as add-on to stand-
ard therapy of gemcitabine/cisplatin in chemotherapy-naive 
patients with advanced biliary tract cancer: an open-label, 
phase I trial with an extensive biomarker program. BMC Can-
cer. 2019;19:55.
9.  Peck J, Wei L, Zalupski M, O’Neil B, Villalona Calero M, 
Bekaii-Saab T. HER2/neu may not be an interesting target in 
biliary cancers: results of an early phase II study with lapat-
inib. Oncology. 2012;82:175-9.
10.  Pellat A, Vaquero J, Fouassier L. Role of ErbB/HER family of 
receptor tyrosine kinases in cholangiocyte biology. Hepatol-
ogy. 2018;67:762-73.
11.  Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve 
R, Bremmes RM, et al. Epidermal growth factor receptor in 
non-small-cell lung carcinomas: correlation between gene 
copy number and protein expression and impact on progno-
sis. J Clin Oncol. 2003;21:3798-807.
12.  Ruschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, 
Penault-Llorca F, et al. HER2 testing in gastric cancer: a practi-
cal approach. Mod Pathol. 2012;25:637-50.
13.  Bartley AN, Washington MK, Ventura CB, Ismaila N, Colas-
acco C, Benson AB 3rd, et al. HER2 testing and clinical deci-
References
14     CANCER  RESEARCH  AND  TREATMENT
sion making in gastroesophageal adenocarcinoma: guideline 
from the College of American Pathologists, American Soci-
ety for Clinical Pathology, and American Society of Clinical 
Oncology. Am J Clin Pathol. 2016;146:647-69.
14.  Sirisinha S, Tengchaisri T, Boonpucknavig S, Prempracha N, 
Ratanarapee S, Pausawasdi A. Establishment and characteri-
zation of a cholangiocarcinoma cell line from a Thai patient 
with intrahepatic bile duct cancer. Asian Pac J Allergy Immu-
nol. 1991;9:153-7.
15.  Sripa B, Leungwattanawanit S, Nitta T, Wongkham C, Bhu-
dhisawasdi V, Puapairoj A, et al. Establishment and charac-
terization of an opisthorchiasis-associated cholangiocarcino-
ma cell line (KKU-100). World J Gastroenterol. 2005;11:3392-7.
16.  Liu X, Ory V, Chapman S, Yuan H, Albanese C, Kallakury B, 
et al. ROCK inhibitor and feeder cells induce the conditional 
reprogramming of epithelial cells. Am J Pathol. 2012;180:599-
607.
17.  Saunders JH, Onion D, Collier P, Dorrington MS, Argent RH, 
Clarke PA, et al. Individual patient oesophageal cancer 3D 
models for tailored treatment. Oncotarget. 2017;8:24224-36.
18.  Chou TC. Drug combination studies and their synergy 
quantification using the Chou-Talalay method. Cancer Res. 
2010;70:440-6.
19.  Zografos GN, Farfaras A, Zagouri F, Chrysikos D, Karaliotas 
K. Cholangiocarcinoma: principles and current trends. Hepa-
tobiliary Pancreat Dis Int. 2011;10:10-20.
20.  Yang X, Wang W, Wang C, Wang L, Yang M, Qi M, et al. Char-
acterization of EGFR family gene aberrations in cholangiocar-
cinoma. Oncol Rep. 2014;32:700-8.
21.  Komoto M, Nakata B, Nishii T, Kawajiri H, Shinto O, Amano 
R, et al. In vitro and in vivo evidence that a combination of 
lapatinib plus S-1 is a promising treatment for pancreatic can-
cer. Cancer Sci. 2010;101:468-73.
22.  Yokoyama M, Ohnishi H, Ohtsuka K, Matsushima S, Ohkura 
Y, Furuse J, et al. KRAS mutation as a potential prognostic 
biomarker of biliary tract cancers. Jpn Clin Med. 2016;7:33-9.
23.  Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska 
D, et al. Emergence of KRAS mutations and acquired resi-
stance to anti-EGFR therapy in colorectal cancer. Nature. 
2012;486:532-6.
24.  Canale M, Petracci E, Delmonte A, Chiadini E, Dazzi C, Papi 
M, et al. Impact of TP53 mutations on outcome in EGFR- 
mutated patients treated with first-line tyrosine kinase 
inhibitors. Clin Cancer Res. 2017;23:2195-202.
25.  Royds JA, Iacopetta B. p53 and disease: when the guardian 
angel fails. Cell Death Differ. 2006;13:1017-26.
26.  Hientz K, Mohr A, Bhakta-Guha D, Efferth T. The role of p53 
in cancer drug resistance and targeted chemotherapy. Onco-
target. 2017;8:8921-46.
27.  Kim Y, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Efficacy and 
safety of afatinib for EGFR-mutant non-small cell lung can-
cer, compared with gefitinib or erlotinib. Cancer Res Treat. 
2019;51:502-9.
28.  Lu X, Liu J, Legerski RJ. Cyclin E is stabilized in response to 
replication fork barriers leading to prolonged S phase arrest. J 
Biol Chem. 2009;284:35325-37.
29.  Li T, Ling YH, Goldman ID, Perez-Soler R. Schedule- 
dependent cytotoxic synergism of pemetrexed and erlotinib 
in human non-small cell lung cancer cells. Clin Cancer Res. 
2007;13:3413-22.
30.  Ubezio P, Falcetta F, Carrassa L, Lupi M. Integrated experi-
mental and simulation study of the response to sequential 
treatment with erlotinib and gemcitabine in pancreatic can-
cer. Oncotarget. 2016;7:15492-506.
31.  Xiang T, Li L, Yin X, Yuan C, Tan C, Su X, et al. The ubiquitin 
peptidase UCHL1 induces G0/G1 cell cycle arrest and apopto-
sis through stabilizing p53 and is frequently silenced in breast 
cancer. PLoS One. 2012;7:e29783.
32.  Kitchen P, Lee KY, Clark D, Lau N, Lertsuwan J, Sawasdichai 
A, et al. A runaway PRH/HHEX-Notch3-positive feedback 
loop drives cholangiocarcinoma and determines response to 
CDK4/6 inhibition. Cancer Res. 2020;80:757-70.
33.  Hynes NE, MacDonald G. ErbB receptors and signaling path-
ways in cancer. Curr Opin Cell Biol. 2009;21:177-84.
Cancer Res Treat. 2020 Oct 7 [Epub ahead of print] 
